×
ADVERTISEMENT

AUGUST 7, 2018

FDA: Increased Risk for Cancer Relapse With Long-Term Use of Azithromycin in Stem Cell Transplants

By Marie Rosenthal

The FDA issued a warning against the long-term use of azithromycin (Zithromax, Pfizer) to prevent bronchiolitis obliterans syndrome in patients with hematologic malignancies who undergo a donor stem cell transplant. The medication is not indicated for this treatment.

Results of a clinical study, which attempted to prevent this serious lung condition with azithromycin prophylaxis, found an increased rate of cancer relapse, including death, in these patients.